Association of bone turnover markers and arterial stiffness in pre-dialysis chronic kidney disease (CKD)

Bone

Volumn 48, Issue 5, 2011, Pages 1127-1132

  Manghat, P ^a   Souleimanova, I ^a   Cheung, J ^a   Wierzbicki, A S ^a   Harrington, D J ^a   Shearer, M J ^a   Chowiencki, P ^a   Fogelman, I ^b   Nerlander, M ^b   Goldsmith, D ^b   Hampson, G ^a,b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

Bone turnover markers; Chronic kidney disease; Fetuin A; FGF 23; Matrix gla protein

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; BONE SPECIFIC ALKALINE PHOSPHATASE; FETUIN A; FIBROBLAST GROWTH FACTOR 23; HORMONE; MATRIX GLA PROTEIN; PHOSPHATE REGULATING HORMONE; PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTERIAL STIFFNESS; ARTICLE; BONE DENSITY; BONE TURNOVER; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIALYSIS; DISEASE ASSOCIATION; FEMALE; FEMUR NECK; FOREARM; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROTEIN BLOOD LEVEL;

ACID PHOSPHATASE; ALKALINE PHOSPHATASE; ARTERIES; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; DEMOGRAPHY; FEMALE; HUMANS; ISOENZYMES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RENAL DIALYSIS;

EID: 79954588905     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.01.016     Document Type: Article

References (41)

1. Schiffrin E.L., Lipman M.L., Mann J.F.E. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007, 116:85-97.
2. Mizobuchi M., Tpwler D., Slatopolsky E. Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol 2009, 20:1453-1464.
3. Covic A., Kanbay M., Voroneanu L., Turgut F., Serban D.N., Serban L.L., et al. Vascular calcification in chronic kidney disease. Clin Sci 2010, 119:111-121.
4. Persy V., D'Hease P. Vascular calcification and bone disease: the calcification paradox. Trends Mol Med 2009, 15(9):405-416.
5. Frost M., Grella R., Millasseau S., Jiang B.Y., Hampson G., Fogelman I., et al. Relationship of calcification of atherosclerotic plaque and arterial stiffness to bone mineral density and osteoproptegerin in postmenopausal women referred for osteoporosis screening. Calcif Tissue Int 2008, 83(2):112-120.
6. Adragao T., Branco P., Birne R., Curto J.D., De Almeida E., Prata M.M., et al. Bone mineral density, vascular calcifications, and arterial stiffness in peritoneal dialysis patients. Perit Dial Int 2008, 668-670.
7. Johnson Rc., Leopold J.A., Loscalzo J. Vascular calcification: pathological mechanisms and clinical implications. Circ Res 2006, 99:1044-1059.
8. Price P.A., Lim J.E. The inhibition of calcium phosphate precipitation by Fetuin is accompanied by the formation of a Fetuin-Mineral complex. J Biol Chem 2003, 278(24):22144-22152.
9. Juppner H., Wolf M., Salusky I.B. FGF-23: more than a regulator of renal phosphate handling?. J Bone Miner Res 2010, 25(10):2091-2097.
10. Wesseling-PERRY k, Pereira R.C., Wang H., Elashoff R.M., Sahney S., Gales B., et al. Relationship between plasma FGF-23 concentration and bone mineralisation in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 2009, 94(2):511-517.
11. Nasrallah M.M., El-Shehaby A.R., Salem M.M., Osman N.A., Sheikh E.E., Sharaf El Din U.A.A. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol Dial Transplant 2010, 25:2679-2685.
12. Manghat P., Fraser W.D., Wierzbicki A.S., Fogelman I., Goldsmith D.J., Hampson G. Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int 2010, 21:1853-1861.
13. Sp Conway, Sp Wolfe, Brownlee K.G., White H., Oldroyd B., Truscott J.G., Harvey J.M., Shearer M.J. Vitamin K status among children with cystic fibrosis and its relationship to bone mineral density and bone turnover. Pediatrics 2005, 115:1325-1331.
14. Millasseau S.C., Kelly R.P., Ritter J.M., Chowienczyk P.J. Determination of age-related increases in large artery stiffness by digital pulse contour analysis. Clin Sci 2002, 103:371-377.
15. Sollinger D., Mohaupt M.G., Wilhelm A., Uehlinger D., Frey F.J., Eisenberger U. Arterial stiffness assessed by digital volume pulse correlates with comorbidity in patients with ESRD. Am J Kidney Dis 2006, 48(3):456-463.
16. Gunarathne A., Patel J.V., Hughes E.A., Lip G.Y. Measurement of stiffness index by digital volume pulse analysis technique: clinical utility in cardiovascular disease risk stratification. Am J Hypertens 2008, 21(8):866-872.
17. Davies M.R., Lund R.J., Mathew S., Hruska K.A. Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J Am Soc Nephrol 2005, 16:917-928.
18. Isakova T., Gutierrez O.M., Wolf M. A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kid Int 2009, 76:705-716.
19. Eddington H., Sinha S., Li E., Hegarty J., Ting J., Lane B., et al. Factors associated with vascular stiffness: cross-sectional analysis from the chronic renal insufficiency standards implementation study. Nephron Clin Pract 2009, 112:c190-c198.
20. Fahrleitner-Pammer A., Herberth J., Browning S.R., Obermayer-Pietsch B., Wirnsberger G., Holzer H., Dobnig H., Malluche H.H. Bone markers predict cardiovascular events in chronic kidney disease. J Bone Miner Res 2008, 23:1850-1858.
21. Briet M., Maruani G., Collin C., Bozec E., Gauci C., Boutouyrie P., et al. Age-independent association between arterial and bone remodelling in mild-to-moderate chronic kidney disease. Nephrol Dial Transplant 2010, 25:191-197.
22. Tomiyama C., Carvalho A.B., Higa A., Jorgetti V., Draibe S.A., Canziani M.E.F. Coronary calcification is associated with lower bone formation rate in CKD patients not yet in dialysis treatment. J Bone Miner Res 2010, 25(3):499-504.
23. Hofbauer L.C., Brueck C.C., Shanahan C.M., Schoppet M., Dobnig H. Vascular calcification and osteoporosis-from clinical observation towards molecular understanding. Osteoporos Int 2007, 18:251-259.
24. Toussaint N.D., Lau K.K., Strauss B.J., Polkinghorne K.R., Kerr P.G. Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrol Dial Transplant 2008, 23(2):586-593.
25. Raggi P., Bellasi A., Ferramosca E., Block G.A., Muntner P. Pulse wave velocity is inversely related to vertebral bone density in hemodialysis patients. Hypertension 2007, 49(6):1278-1284.
26. Yamaguchi T., Kanno E., Tsubota J., et al. Retrospective study on the usefulness of radius and lumbar spine density in the separation of hemodialysis patients with fractures from those without fractures. Bone 1996, 19:549-555.
27. Cozzolino M., Mazzaferro S., Pugliese F., Brancaccio D. Vascular calcification and uremia: what do we know?. Am J Nephrol 2008, 28:339-346.
28. Shanahan C.M., Cary N.R., Metcalfe J.C., Weissberg P.L. High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest 1994, 93:2393-2402.
29. Parker B.D., Ix J.H., Cranenburg E.C.M., Vermeer C., Whooley M.A., Schurgers L.J. Association of kidney function and uncarboxylated matrix gla protein: data from the heart and soul study. Nephrol Dial Transplant 2009, 24:2095-2101.
30. Hermans M.M., Vermeer C., Kooman Jp., Brandenburg V., Ketteler M., Gladziwa U., Rensma P.L., Leunissen K.M., Schurgers Lj. Undercarboxylated matrix GLA protein levels are decreased in dialysis patients and related to parameters of calcium-phosphate metabolism and aortic augmentation index. Blood Purif 2007, 25(5-6):395-401.
31. Schurgers L.J., Teunissen K.J.F., Knapen M.H.J., Geusens P., Van Der Heidje D., Kwaijtaal M., et al. Characteristics and performance of an immunosorbent assay for human matrix gla-protein. Clin Chim Acta 2005, 351:131-138.
32. Schurgers L.J., Barreto D.V., Barreto F.C., Liabeuf S., Renard C., Magdeleyns E.J., et al. The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin J Am Soc Nephrol 2010, 5(4):568-575.
33. Braam L.A., Dissel P., Gijsbers B.L., Spronk H.M., Hamulyak K., Soute B.A., et al. Assay for human matrix gla protein in serum: potential applications in the cardiovascular field. Arterioscler Thromb Vasc Biol 2000, 20(5):1257-1261.
34. Cranenburg E.C.M., Koos R., Schurgers L.J., Magdeleyns E.J., Schoonbrood T.H.M., Robert B., et al. Characterisation and potential diagnostic value of circulating matrix gla protein (MGP) species. Thromb Haemost 2010, 104:811-822.
35. Schurgers L.J., Cranenburg E.C.M., Vermeer C. Matrix gla-protein: the calcification inhibitor in need of vitamin K. Thromb Haemost 2008, 100:593-603.
36. O'Donnell C.J., Shea M.K., Price P.A., Gagnon D.R., Wilson P.W.F., Larson M.G., et al. Matrix gla protein is associated with risk factors for atherosclerosis but not with coronary artery calcification. Arterioscler Thromb Vasc Biol 2006, 26:2769-2774.
37. Mehrotra R. Emerging role for fetuin-A as contributor to morbidity and mortality in chronic kidney disease. Kidney Int 2007, 72:137-140.
38. Pereira P.C., Juppner H., Azucena-Serrano C.E., Yadin O., Salusky I.B., Wesseling-Perry K. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone 2009, 45:1161-1168.
39. Kirkpantur A., Balci M., Gurbuz O.A., Afsar B., Canbakan B., Akdemir R., et al. Serum fibroblast growth factor-23 (FGF-23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haemodialysis patients. Nephrol Dial Transplant 2010, 26:1346-1354.
40. Parker B.D., Schurgers L.J., Brandenburg V.M., Christenson R.H., Vermeer C., Ketteler M., et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix gla protein with mortality in coronary artery disease: the heart and soul study. Ann Intern Med 2010, 152:640-648.
41. Gutierrez O.M., Januzzi J.L., Isakova T., Laliberte K., Smith K., Collerone G., et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009, 119:2545-2552.